日本批准在2024年10月分发Kostaive(ARCT-154)疫苗,这是针对Omicron的自我强化的MRNA COVID-19疫苗。 Japan approves Kostaive (ARCT-154), a self-amplifying mRNA COVID-19 vaccine targeting Omicron, for distribution in October 2024.

日本已经批准了Kostaive(ARCT-154),这是由CSL和Arcturus治疗公司研制的针对JN.1微菌菌株的首种自我强化的MRNA COVID-19疫苗。 Japan has approved Kostaive (ARCT-154), the first self-amplifying mRNA COVID-19 vaccine, developed by CSL and Arcturus Therapeutics, targeting the JN.1 Omicron strain. 梅吉赛卡制药公司将在2024年10月的疫苗接种活动中分发,与传统的mRNA增强剂相比,该疫苗具有更高的免疫性. Set for distribution by Meiji Seika Pharma in the October 2024 vaccination campaign, this vaccine has shown superior immunogenicity compared to conventional mRNA boosters. 卫生部小组建议更新Omicron亚变差剂的疫苗,随后批准。 Approval follows a health ministry panel's recommendation to update vaccines for Omicron subvariants.